OC 18.3 Targeting of liver sinusoidal endothelial cells (LSECs) with a bioengineered AAV capsid for hemophilia A gene therapy
Jonathan Lindgren, Yong Hong Chen, Brian Lewandowski, Beverly L. Davidson, Denise E. Sabatino
Children's Hospital of Philadelphia University of Pennsylvania
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
The endogenous site of factor VIII (FVIII) synthesis is the liver sinusoidal endothelial cell (LSEC). Current AAV gene therapy approaches use serotypes that efficiently target hepatocytes with hepatocyte specific promoter elements. However, naturally occurring AAV serotypes do not effectively target LSECs, limiting their ability to deliver FVIII expression to its physiological cellular source.
逐年被引趋势
暂无年度引用数据
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Hemophilia Treatment and Research
Virus-based gene therapy research · RNA Interference and Gene Delivery